Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – Stock analysts at Piper Jaffray Companies increased their Q2 2019 earnings estimates for Catalyst Pharmaceuticals in a research note issued to investors on Monday, May 13th, Zacks Investment Research reports. Piper Jaffray Companies analyst J. Catanzaro now anticipates that the biopharmaceutical company will post earnings of $0.03 per share for the quarter, up from their prior estimate of ($0.05). Piper Jaffray Companies also issued estimates for Catalyst Pharmaceuticals’ Q3 2019 earnings at $0.03 EPS, Q4 2019 earnings at $0.04 EPS and FY2019 earnings at $0.09 EPS.
A number of other analysts also recently commented on CPRX. BidaskClub raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, February 25th. ValuEngine downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, April 1st. Zacks Investment Research raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a report on Tuesday, May 21st. Cantor Fitzgerald reissued a “buy” rating and set a $10.00 price objective on shares of Catalyst Pharmaceuticals in a report on Tuesday, March 19th. Finally, HC Wainwright set a $9.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, May 14th. Seven research analysts have rated the stock with a buy rating, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average target price of $7.35.
Shares of NASDAQ:CPRX traded up $0.05 during midday trading on Wednesday, hitting $3.43. The stock had a trading volume of 2,730,680 shares, compared to its average volume of 2,097,027. The company has a market cap of $352.79 million, a price-to-earnings ratio of -10.39 and a beta of 2.71. The company has a quick ratio of 6.07, a current ratio of 6.08 and a debt-to-equity ratio of 0.02. Catalyst Pharmaceuticals has a 1 year low of $1.85 and a 1 year high of $6.16.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Monday, May 13th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.12. The business had revenue of $12.45 million during the quarter, compared to analyst estimates of $2.40 million. During the same quarter in the prior year, the firm posted ($0.06) earnings per share.
Several hedge funds and other institutional investors have recently made changes to their positions in CPRX. Amalgamated Bank purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $28,000. Paloma Partners Management Co acquired a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $30,000. Metropolitan Life Insurance Co. NY raised its position in shares of Catalyst Pharmaceuticals by 291.8% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 27,253 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 20,297 shares during the last quarter. Meeder Asset Management Inc. raised its position in shares of Catalyst Pharmaceuticals by 185.1% in the fourth quarter. Meeder Asset Management Inc. now owns 34,237 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 22,227 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Catalyst Pharmaceuticals by 18.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 36,700 shares of the biopharmaceutical company’s stock valued at $70,000 after buying an additional 5,688 shares during the last quarter. 59.79% of the stock is currently owned by institutional investors.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.